PUBLISHER: The Business Research Company | PRODUCT CODE: 1763083
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763083
Nplate and Romiplate (romiplostim) are biologic drugs classified as thrombopoietin receptor agonists, used to treat immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, increasing the risk of bleeding. Romiplostim stimulates platelet production in the bone marrow, helping maintain a safe platelet count in patients with chronic ITP.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary patient groups for nplate and romiplate (romiplostim) include pediatric, adult, and geriatric patients. This includes children and adolescents diagnosed with conditions such as chronic immune thrombocytopenia (ITP) that require Romiplate treatment. Romiplate stimulates platelet production, making it a crucial therapy for younger patients with low platelet counts. Pediatric patients may need specific dosages and close monitoring due to their developing bodies. It is used for various conditions, including chronic immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and others, and is available through hospital, retail, and online pharmacies.
The nplate, romiplate (romiplostim) market research report is one of a series of new reports from The Business Research Company that provides nplate, romiplate (romiplostim) market statistics, including the nplate, romiplate (romiplostim) industry's global market size, regional shares, competitors with a nplate, romiplate (romiplostim) market share, detailed nplate, romiplate (romiplostim) market segments, market trends and opportunities, and any further data you may need to thrive in the nplate, romiplate (romiplostim) industry. This nplate, romiplate (romiplostim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The nplate, romiplate (romiplostim) market size is expected to see strong growth in the next few years. It will grow to $1,871.5 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing global healthcare access, growing health economics, increasing biotechnology innovations, growing effective treatments, and increasing blood disorders. Major trends in the forecast period include emerging biosimilars, advancements in treatment protocols, technology integration, drug delivery approach, strategic collaborations, and investments in research and developments.
The increasing incidence of cancer is expected to propel the growth of the nplate, romiplate (romiplostim) market. Cancer refers to a group of diseases characterized by the abnormal and uncontrolled growth of cells. The rise in cancer cases is attributed to factors such as an aging population, environmental exposure to carcinogens, unhealthy lifestyle choices (e.g., smoking, poor diet), genetic factors, and advancements in diagnostic techniques that lead to earlier and more frequent cancer detection. Nplate and Romiplate (Romiplostim) stimulate platelet production via the thrombopoietin receptor, which helps cancer patients-especially those undergoing chemotherapy-by reducing the risk of thrombocytopenia (low platelet counts), improving platelet levels, enhancing safety during treatment, and minimizing the need for platelet transfusions. For example, in August 2024, the Australian Institute of Health and Welfare projected that by 2034, Australia would see approximately 209,000 new cancer diagnoses, up from an estimated 169,000 in 2024, reflecting the impact of a growing population and increasing cancer rates. Thus, the rising cancer incidence will drive the nplate, romiplate (romiplostim) market.
Rising healthcare expenditure is expected to propel the growth of the nplate, romiplate (romiplostim) market. Healthcare expenditure refers to the total spending on healthcare goods and services, including personal health care, preventive services, and public health activities aimed at improving health outcomes. The rise in healthcare expenditure is driven by factors such as an aging population, chronic diseases, technological advancements in healthcare, high drug prices, and increased service demand. Rising healthcare expenditure boosts access to advanced biologics like Romiplostim for treating chronic conditions such as Immune Thrombocytopenic Purpura (ITP). For instance, in May 2024, the Office for National Statistics reported a 5.6% increase in total healthcare expenditure in the UK from 2022 to 2023, signaling greater investment in healthcare services, including those related to Romiplostim. This trend will support the growth of the nplate, romiplate (romiplostim) market.
A key trend in the nplate, romiplate (romiplostim) market is the development of Nplate for FDA approval to protect adults and children exposed to acute myelosuppressive doses of radiation. Nplate is now being developed for use in radiological or nuclear emergencies, with an administration kit designed to simplify its delivery. For instance, in October 2023, the Biomedical Advanced Research and Development Authority (BARDA) announced support for the development of the Nplate administration kit. This kit aims to simplify the use of Nplate during radiological or nuclear emergencies, with BARDA procuring additional doses of Nplate as part of Project BioShield. Nplate is approved to increase survival rates in both adult and pediatric patients (including newborns) exposed to myelosuppressive doses of radiation, specifically in cases of Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS). This trend is part of the U.S. government's efforts to enhance preparedness for radiological and nuclear emergencies, which is expected to drive the Nplate, Romiplate (Romiplostim) market.
Major players operating in the nplate, romiplate (romiplostim) market are Novartis AG, Amgen, Intas Pharmaceuticals.
North America was the largest region in the nplate, romiplate (romiplostim) market in 2024. The regions covered in nplate, romiplate (romiplostim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nplate, romiplate (romiplostim) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nplate, romiplate (romiplostim) market consists of sales of the lyophilized powder for injection, nplate 500 mcg, and nplate 125 mcg. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nplate, Romiplate (romiplostim) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nplate, romiplate (romiplostim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for nplate, romiplate (romiplostim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nplate, romiplate (romiplostim) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.